GLP-1 receptor is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2025-11-11. Numbers and descriptions here follow the published literature rather than marketing material.
Tirzepatide is a synthetic peptide built from 39 amino acid residues. Its sequence is related to human glucose-dependent insulinotropic polypeptide, with modifications that include a C-terminal extension and a C20 fatty diacid joined through a linker. Those changes raise the molecule's affinity for serum albumin, which slows renal filtration and lengthens the time it stays in circulation. The free base has an average molecular mass near 4813.5 daltons. The compound is made by solid-phase peptide synthesis followed by chromatographic purification.
At the receptor level, tirzepatide activates both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. Both belong to the class B family of G protein-coupled receptors and signal largely through cyclic AMP accumulation. The compound binds the two receptors with differing affinity, and the pattern of signaling at each site is described in the literature as biased rather than simply proportional to occupancy. Tissues carrying these receptors include pancreatic islets, adipose tissue, the central nervous system, and the gastrointestinal tract. The relative weight of each receptor population in producing metabolic effects continues to be studied.
Published work supports the view that engaging two incretin receptors produces changes in glucose handling and body weight larger than those seen with single-receptor activation. Why that difference arises is not fully settled. Open questions include how much of the observed weight effect depends on central versus peripheral signaling, and whether the two receptors form interacting complexes. Most reported findings come from controlled trials and animal models, and translation between species is imperfect. Further research is expected to refine these points over time.
At the receptor level, the compound binds both GIP and GLP-1 receptors and triggers downstream signalling that raises cyclic AMP in target cells. GLP-1 receptor activation is associated with glucose-dependent insulin release, slower gastric emptying, and reduced appetite signalling. GIP receptor activation contributes effects that are less completely characterised, and how much each receptor adds to the overall clinical response is still an open question. The two pathways appear to interact in a complementary rather than a purely additive way.
An extended fatty diacid moiety promotes binding to serum albumin, which slows renal clearance and extends the circulating half-life to roughly five days. That property supports once-weekly administration and largely explains the dosing interval described in clinical reports. Published data come mainly from large randomised programmes that evaluated glycaemic control and body weight over periods of many months. Long-term outcomes beyond those trial windows, including what happens after treatment stops, remain an active area of investigation.
Tirzepatide is a synthetic peptide built from thirty-nine amino acids. Its sequence is derived from native glucose-dependent insulinotropic polypeptide, or GIP, with several non-natural residues and a fatty diacid side chain attached through a linker. The molecule behaves as a dual agonist at two incretin receptors, GIP and GLP-1, instead of targeting a single receptor. This dual engagement separates it from earlier single-receptor incretin compounds and underpins most of its reported pharmacological activity.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C225H348N48O68 | 39-residue synthetic peptide |
| Average molecular mass | About 4813.5 Da | Free base form |
| Appearance | White to off-white powder | Solid after lyophilization |
| Solubility class | Freely soluble in water | Also soluble in neutral aqueous buffers |
| Typical storage | At or below -20 °C, desiccated | Protect from light and moisture |
Structure-activity work shows that fatty acid length, linker chemistry and the position of acylation all influence albumin affinity and receptor potency. Plasma protein binding exceeds 99 percent, which restricts distribution and slows renal clearance. Degradation proceeds largely through general proteolysis and fatty acid oxidation rather than cytochrome P450 metabolism, so exposure to common oxidative drug interactions is limited. Whether these clearance routes vary meaningfully between individuals is not fully established.
The molecule is a synthetic 39-amino-acid peptide whose backbone derives from the sequence of human glucose-dependent insulinotropic polypeptide, with several substitutions that raise metabolic stability and shift receptor preference. A C20 fatty diacid is attached through a short linker to a lysine side chain, a modification that increases binding to serum albumin. The reported monoisotopic mass is approximately 4813 Da. Near neutral pH the peptide carries a net negative charge, and the lipid tail makes the molecule markedly more hydrophobic than the unmodified parent sequence.
Dual agonism at the GIP and GLP-1 receptors underlies the observed pharmacology. Activation of GLP-1 receptors raises glucose-dependent insulin release, lowers glucagon secretion, slows gastric emptying and reduces appetite. GIP receptor activation contributes additional effects on adipose tissue and on energy balance, and the combined action on appetite appears larger than either pathway alone in animal models. Signalling bias and the relative contribution of each receptor arm to weight-related effects remain areas of active investigation.
Stability depends strongly on physical form. The dry powder is generally regarded as stable for extended periods when held at or below minus twenty degrees Celsius in a sealed, desiccated container. In solution, degradation pathways include deamidation of asparagine and glutamine residues, oxidation of methionine, and aggregation. Reaction rates for these pathways rise with temperature. Repeated freezing and thawing of solutions promotes aggregation, and light exposure can accelerate some oxidative changes. Buffer composition and pH influence which pathway dominates at a given temperature.
Regulatory and quality discussions place the peptide within established guidance for synthetic peptides and biologics. Forced degradation studies, in which samples are exposed to heat, acid, base, peroxide, and light, identify likely degradation products and validate the selectivity of analytical methods. Reference standards allow comparison across laboratories and production batches. Purity specifications reported in the literature usually combine chromatographic purity with mass confirmation. Which impurity thresholds are meaningful for long-term behavior is still debated, and no single universal specification has been adopted across all jurisdictions.
==== JPT2 ==== The 20kDa Jupiter microtubule-associated homolog 2 (JPT2) (also known as HN1L) was the first accessory protein to be published as a mediator of NAADP-dependent Ca2+ release. Both studies exploited the same novel 'clickable' NAADP photoprobe, but regardless of the different blood cell types, the authors converged on the same molecular partner (although the studies differ in the channel that is activated). JPT2 binds [32P]NAADP with selectivity over a spectrum of different nucleotides. In Ca2+-release studies, NAADP-dependent signals were inhibited by siRNA knockdown of JPT2, but not of its homolog, JPT1, attesting to isoform specificity. Interestingly, JPT2 exhibited a preferential interaction with TPC1 over TPC2. Given that TPCs are known to drive pathogen uptake into cells, it was striking that uptake of a Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pseudovirus was likewise reduced by JPT2 gene silencing.
==== International ==== 4-AcO-DMT is not scheduled under any international drug schedules, including the United Nations 1971 Convention on Psychotropic Substances, making it a potentially more accessible alternative to psilocybin for research.
== Ownership of distilleries == A 2016 report stated that only 20% of the whisky was made by companies owned in Scotland. Distilleries owned by Diageo, a London-based company, produce 40% of all Scotch whisky, with over 24 brands, such as Johnnie Walker, J&B and Vat 69. Another 20% of the product is made by distillers owned by Pernod Ricard of France, including brands such as Ballantine's, Chivas Regal and Glenlivet . There are also 12% made by smaller distillers that are owned by foreign companies, such as Cutty Sark and Label 5 owned by La Martiniquaise of France, Dewar's and William Lawson's owned by Bacardi Limited of Bermuda and BenRiach whose parent is the Brown–Forman Corporation based in Kentucky, United States. Nonetheless, Scotch whisky is produced according to the current regulations, as to ageing, production, and so on, ensuring that it remains Scottish. Independents owned by Scots companies make a substantial amount of Scotch whisky, with the largest, William Grant & Sons, producing 8%, or about 7.6 million cases per year. Its brands include Balvenie, Glenfiddich, and Grant's. Glenfiddich is the best-selling single malt Scotch in the world. Roughly 14 million bottles of Glenfiddich are sold annually.
== Reception == Action Half-Life was the favored modification for a small subculture described by Rock, Paper, Shotgun's writer Quintin Smith as a "mad cabal of mappers who obsessed over easter eggs", with some levels containing secret areas much larger and more complex than the main level. These often included whole story-lines, puzzles, and scripted sequences. IGN said the game is a standard shooter aside from the stunts and although they look cool, they get tiresome quickly. PC Games liked the level design and said the game is more suited for experienced players. XtremPC played the beta 2.7 version and said the game is far below the quality of Action Quake 2. CNET Gamecenter placed it on its list of top 10 Half-Life mods, writing: "Action Half-Life, however, manages to capture a sense of danger and suspense that's missing from most frag-a-minute deathmatches."
Sources: en.wikipedia.org
Biological value (BV) is a measure of the proportion of absorbed protein from a food which becomes incorporated into the proteins of the organism's body. It captures how readily the digested protein can be used in protein synthesis in the cells of the organism. Proteins are the major source of nitrogen in food. BV assumes protein is the only source of nitrogen and measures the amount of nitrogen ingested in relation to the amount which is subsequently excreted. The remainder must have been incorporated into the proteins of the organisms body. A ratio of nitrogen incorporated into the body over nitrogen absorbed gives a measure of protein "usability" – the BV. Unlike some measures of protein usability, biological value does not take into account how readily the protein can be digested and absorbed (largely by the small intestine). This is reflected in the experimental methods used to determine BV. BV uses two similar scales:
== Properties == Metalloids usually look like metals but behave largely like nonmetals. Physically, they are shiny, brittle solids with intermediate to relatively good electrical conductivity and the electronic band structure of a semimetal or semiconductor. Chemically, they mostly behave as (weak) nonmetals, have intermediate ionization energies and electronegativity values, and amphoteric or weakly acidic oxides. Most of their other physical and chemical properties are intermediate in nature.
Most of the high or low affinity bindings require chelation or competitive titration. This method is done by loading pre-bound complex solution in the sample cell and chelating one of the components out with a reagent of higher observed binding affinity within the desirable c-window. In order to ensure optimum instrument stability, the ITC instrument should be powered on at least one day before use. Samples should ideally be pre-equilibrated to approximately 2 °C below the target experimental temperature to reduce stabilization time after loading, although starting at the exact experimental temperature is also an option. For instrument cleaning, sample cell should be rinsed with the experimental buffer and dried under vacuum, and any remaining rinsed solution should be discarded manually with a syringe. Then, the sample cell is filled with the experimental solution and the reference cell with either high-purity water or the same buffer. To prevent air contamination, gas-tight Hamilton syringes are used, ensuring the needle is positioned near the bottom of the sample cell before dispensing the liquid slowly. Experimental parameters such as the number of injections, initial injection volume, subsequent injection volumes, temperature, reference power, stirring speed, spacing, initial delay, and filter period should be adjusted according to the specific study. If the experiment is to be repeated, the syringe should be emptied, with the solution either discarded or saved for further analysis.
=== Phase 2 clinical trial – Covid-19 / SARS-CoV-2 === The Brilacidin trial for the treatment of COVID-19 infection has started in February 2021 and is expected to be completed in July 2021. The study is a randomized, blinded, placebo-controlled, parallel group design and will accept 120 patients. The placebo or drug will be administered via IV infusion to patients with moderate to severe COVID-19, SARS-CoV-2 infection confirmed by positive standard polymerase chain reaction test (or equivalent/ other approved diagnostic test) within 4 days prior to starting study treatment, and hospitalized with respiratory distress but not yet requiring high-level respiratory support.
== Pathophysiology == SJS is a type IV hypersensitivity reaction in which a drug or its metabolite stimulates cytotoxic T cells (i.e. CD8+ T cells) and T helper cells (i.e. CD4+ T cells) to initiate autoimmune reactions that attack self tissues. In particular, it is a type IV, subtype IVc, delayed hypersensitivity reaction dependent in part on the tissue-injuring actions of natural killer cells. This contrasts with the other types of SCARs disorders, i.e., the DRESS syndrome which is a Type IV, Subtype IVb, hypersensitivity drug reaction dependent in part on the tissue-injuring actions of eosinophils and acute generalized exanthematous pustulosis which is a Type IV, subtype IVd, hypersensitivity reaction dependent in part on the tissue-injuring actions of neutrophils. Like other SCARs-inducing drugs, SJS-inducing drugs or their metabolites stimulate CD8+ T cells or CD4+ T cells to initiate autoimmune responses. Studies indicate that the mechanism by which a drug or its metabolites accomplishes this involves subverting the antigen presentation pathways of the innate immune system. The drug or metabolite covalently binds with a host protein to form a non-self, drug-related epitope. An antigen presenting cell (APC) takes up these alter proteins; digests them into small peptides; places the peptides in a groove on the human leukocyte antigen (i.e. HLA) component of their major histocompatibility complex (i.e. MHC); and presents the MHC-associated peptides to T-cell receptors on CD8+ T cells or CD4+ T cells.
Sources: en.wikipedia.org
It is a synthetic peptide and a dual agonist of two incretin receptors. It is not a small molecule, and it is not structurally related to the older single-receptor peptide agonists.
The C20 fatty diacid promotes tight binding to serum albumin. That binding reduces renal clearance and extends circulation time compared with an unmodified peptide of similar length.
It is not fully established. Studies indicate that both receptors contribute to the observed effects, but the exact split between the two signaling pathways in humans remains an open question.
It acts as a dual agonist at the GIP receptor and the GLP-1 receptor. This broader targeting profile distinguishes it from selective GLP-1 agonists, which engage only one receptor.